Abstract: OBJECTIVE To observe the clinical distribution characteristics of multidrug-resistant Acinetobacter baumannii, and monitor and analyze its drug resistance. METHODS From Jan. 2013 to Dec. 2015, 1771 cases of clinical specimens infected with A. baumannii were selected. The specimen source and drug sensitivity were retrospectively analyzed. RESULTS From 1771 specimens, 1771 strains of A. baumannii were detected, of which 879 strains were multidrug-resistant A. baumannii, accounting for 49.6%, and 46.8% in 2013, 48.1% in 2014, and 53.1% in 2015. From 2013 to 2015, multidrug-resistant A.baumannii was mainly detected in sputum, which was above 70.0%. Multidrug-resistant A. baumannii was mainly in ICU, accounting for above 30%. Drug resistant rates of multidrug-resistant A.baumannii to ampicillin and piperacillin were above 90.0%, and multidrug-resistant A.baumannii was sensitive to tigecycline, amikacin, imipenem and meropenem, and drug resistant rates were less than 40.0%. Drug resistant rates of multidrug-resistant A.baumannii to tigecycline, imipenem and meropenem were increased from 2013 to 2015. CONCLUSION Hospital multidrug resistant A. baumannii was mainly isolated from the sputum and distributed in ICU, and its drug resistance is serious, which should be paid attention in clinic.